NCT01457560CompletedPhase 3
Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 80
- Primary Endpoint
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
Study Overview
Brief Summary
This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month of life. The last dose of DTPa-HBV-IPV/Hib will be given simultaneously with one dose of OPV vaccine.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 12 Weeks to 16 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The inclusion criteria will be checked at study entry. If any of these criteria does not apply, the subject is not eligible for inclusion in the study.
- •Healthy male and female subjects in the ≥12 and <16 weeks of life at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the parents/guardians of the infant after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.
Exclusion Criteria
- •The exclusion criteria will be checked at study entry and at each following visit. If any of these criteria applies at study entry, the subject is not eligible for inclusion in the study. If any of these criteria becomes applicable during the study, the subject should be withdrawn.
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Administration of chronic immunosuppressants or other immune-modifying drugs within three months before vaccination).
- •Administration of a vaccine not foreseen by the study within 30 days before each dose of the study vaccines and ending 30 days after.
- •Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
- •History of /or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease or infection.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of seizures or of any neurological disease at study entry.
- •Administration of immunoglobulins and/or any blood products since birth, or planned administration during the study period.
- •Acute disease at the time of enrolment.
Arms & Interventions
Group A
Experimental
Intervention: DTPa-HBV-IPV/Hib (Infanrix hexa™) (Biological)
Group A
Experimental
Intervention: OPV (Biological)
Outcomes
Primary Outcomes
Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
Time Frame: One month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9)
Secondary Outcomes
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with vaccine response(One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).)
- Number of subjects with serious adverse events(During the study period (Month 0 to Month 9))
- Immunogenicity with respect to the components of the study vaccine in terms of antibody titres greater than or equal to cut off values(One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).)
- Number of subjects with solicited and unsolicited adverse events(After each dose of the study vaccines (Month 0, Month 3 and Month 9) and overall)
- Immunogenicity with respect to the components of the study vaccine in terms of antibody titers(Before the first dose (Month 0), one month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9).)
- Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values(Before the first dose ( Month 0 ))
Investigators
Similar Trials
Completed
Phase 3
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyTetanusDiphtheriaPertussisHaemophilus Influenzae Type b (Hib)PoliomyelitisHepatitis BNCT01457508GlaxoSmithKline440
Completed
Phase 2
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyHaemophilus Influenzae Type b (Hib)PoliomyelitisTetanusHepatitis BDiphtheriaPertussisNCT01457495GlaxoSmithKline312
Completed
Phase 3
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsInfections, StreptococcalNCT00390910GlaxoSmithKline286
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenInfluenzaNCT01196988GlaxoSmithKline3,027
Completed
Phase 3
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenMumpsRubellaMeaslesVaricellaNCT01506193GlaxoSmithKline716